VM 1500

Drug Profile

VM 1500

Alternative Names: Elpida; elpivirine; RO 4970335; RO 5011500; VM 1500a; VM-1500; VM-1500 LAI; VM-1500 Long acting injectable; VM-1501

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Viriom
  • Class Antivirals; Small molecules
  • Mechanism of Action HIV reverse transcriptase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in Russia (Topical, Gel)
  • 11 May 2016 Pharmacokinetics data released by Viriom
  • 15 Dec 2015 Efficacy and adverse events data from a phase II/III trial in HIV infections (Combination therapy, Treatment-naive) released by Viriom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top